Formal Patient Education Improves Patient Knowledge of Hepatitis C in Vulnerable Populations by Surjadi, Miranda et al.
ORIGINAL ARTICLE
Formal Patient Education Improves Patient Knowledge
of Hepatitis C in Vulnerable Populations
Miranda Surjadi • Cara Torruellas •
Claudia Ayala • Hal F. Yee Jr. • Mandana Khalili
Received: 2 June 2010/Accepted: 5 October 2010/Published online: 24 October 2010
 The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract
Background Hepatitis C (HCV) knowledge is limited
in injection drug users (IDU). Vulnerable populations
including IDUs are disproportionally affected by HCV.
Effective HCV education can potentially reduce disparity
in HCV prevalence and its outcome in this population.
Aim This study aimed to assess the impact of formal
HCV education and factors associated with improved HCV
knowledge in the vulnerable population.
Methods Over 18 months, 201 HCV-infected patients
underwent a 2-h standardized education and completed
demographic and pre- and post-education questionnaires.
Results Patient characteristics were: 69% male, mean age
49 ± 10, 49% White (26% AA, 10% Latino), 75% unem-
ployed, 83% high school education and above, 64% were
IDU, and 7% were HIV co-infected. On multivariate anal-
ysis, baseline knowledge scores were higher in patients with
at least a high school education (coef 7.1, p = 0.045).
BaselineknowledgescoreswerelowerinAfricanAmericans
(coef -12.3, p = 0.004) and older patients (coef -0.7,
p = 0.03).FollowingHCVeducation,theoveralltestscores
improved signiﬁcantly by 14% (p = 0.0001) speciﬁcally in
the areas of HCV transmission (p = 0.003), general knowl-
edge (p = 0.02), and health care maintenance (p = 0.004).
There was a high compliance with liver specialty clinic
attendance following education.
Conclusions Formal HCV education is effective in
improving HCV knowledge. Although White race, younger
age, and higher education were predictors of having more
HCV knowledge prior to education, all patients indepen-
dent of racial background had a signiﬁcant improvement in
their knowledge after education. Therefore, promoting
effective HCV education among vulnerable populations
may be an important factor in reducing the disparities in
HCV disease.
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Introduction
Hepatitis C virus (HCV) affects 4.1 million Americans and
is the leading cause of chronic liver disease and death from
liver disease in the country [1]. The diagnosis of hepatitis C
can also affect a person’s quality of life, ﬁnances, pro-
ductivity, and psychological status [2, 3]. Prior studies have
shown that HCV-infected individuals have limited knowl-
edge of HCV disease and improvement in HCV knowledge
can inﬂuence a patient’s decision to explore and initiate
HCV therapy [4, 5].
The majority of studies evaluating the impact of HCV
education on patients’ health have focused on injection
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DOI 10.1007/s10620-010-1455-3drug users (IDUs) and often within the context of drug
treatment programs [6, 7]. IDUs are considered hard to
reach populations with a high prevalence of HCV infection
[8]. Drug treatment programs therefore represent an
opportunity for providing health care to these individuals.
In addition, many IDUs are actively using drugs at the time
of HCV diagnosis, thereby education about modes of
transmission of HCV is important to prevention of trans-
mission of HCV in this population. Studies to date have
shown that IDUs have many misconceptions about HCV
transmission, symptoms, clinical markers, and treatment,
including a perceived fear of HCV treatment [4, 9]. These
individuals are generally interested in educational services
and improved knowledge of HCV disease is associated
with increasing interest in receipt of HCV treatment
[7, 10].
Although IDUs are considered a vulnerable population
and represent the majority of HCV-infected individuals
within the safety net system, these ﬁndings may not
necessarily be applicable to other non-IDU vulnerable
populations with HCV infection who are uninsured or
underinsured with limited access to care. In addition, while
HCV education can vary among different health systems
and studies have shown that patients attending liver spe-
cialty clinics have higher HCV knowledge compared to
those in the primary care setting, there are reports of sub-
optimal (60%) rates of formal education among patients
attending specialty clinics [11]. The purpose of this study
was to prospectively evaluate the impact of formal HCV
education given by liver specialty providers on patient’s
knowledge of hepatitis C disease and interest in pursuing
liver specialty care for evaluation of HCV therapy among a
large cohort of vulnerable and ethnically diverse safety net
population.
Methods
Subject Eligibility
The Hepatology service at San Francisco General Hospital
and Trauma Center, a safety net institution afﬁliated with
University of California San Francisco (UCSF), instituted a
formal HCV education session accessible to all HCV-
infected individuals within San Francisco’s safety net
healthcare system. The initial diagnosis of HCV infection
was made by the primary providers. Primary providers
refer their adult patients for HCV education prior to being
permitted to have their patients scheduled for the liver
specialty clinics. Patients who attend the education session
may or may not be candidates for HCV therapy but referral
to liver specialty clinics are primarily made for consider-
ation for initiation of HCV therapy.
The study population consisted of subjects attending this
educational session. All study participants provided
informed consent prior to enrollment. This study was
approved by the UCSF Committee on Human Research and
SFGH Data Governance Committee.
Education Session
The HCV education session consisted of a 2-h standardized
in-person didactic PowerPoint presentation facilitated by a
specialized hepatology nurse practitioner. Up to 25 subjects
attended each session. The session was offered in English
and with the aid of certiﬁed interpreters in Spanish, Can-
tonese, and Vietnamese. Subjects were encouraged to ask
questions during the session and each session was followed
by an interactive discussion. The educational materials
consisted of information on HCV diagnosis, symptoms,
transmission, natural history, assessment of severity of
liver disease and candidacy for treatment, virologic
response rates with PEGylated interferon and ribavirin
combination therapy, adverse effects of treatment, and
resources for obtaining further HCV healthcare and spe-
cialty access.
Data Collection Procedures
Participants completed a demographic questionnaire at
baseline followed by a questionnaire assessing HCV
knowledge as well as interest in obtaining HCV care and
treatment both before (pre-education) and immediately
after (post-education) completion of the session (Table 1).
The questionnaire was developed by study investigators,
reviewed by three hepatology providers and pilot tested in
20 patients and revised. Subjects who then attended the
liver specialty clinic were asked to complete another post-
education questionnaire at the time of their clinic visit in
order to assess the retention of knowledge overtime. The
pre-education and post-education questionnaires consisted
of 31 multiple-choice and true/false questions. The total
number of correct answers was then scored for overall
knowledge and also in the following knowledge categories
(assigned by the investigators): HCV general knowledge,
HCV diagnosis, HCV transmission, HCV treatment, and
health care maintenance.
Statistical Analysis
Baseline characteristics of subjects were summarized
using mean ± SD, median (range), and frequencies.
Paired t test was used to assess the change in knowledge
score after education overall and within each knowledge
categories. Univariate analysis using t test and analysis of
variance was performed evaluating factors associated with
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score following education. Multivariate regression model-
ing was used to evaluate factors independently associated
with pre-education score and change in knowledge score
following education. A p value\0.05 was considered
statistically signiﬁcant. All analysis was performed
using STATA version 8.0 (STATA Corp., College Sta-
tion, TX).
Results
From October 2007 to June 2009, 201 HCV-infected sub-
jects who attended the HCV education session participated
in the study and 197 subjects completed both pre-education
and post-education questionnaires. Subjects were mostly
middle-aged males who were unemployed with incomes of
less than $15,000 per year (Table 2). Approximately half
of the subjects were minorities and had high school or
higher education. About two-thirds had a history of IDU
and heavy alcohol use. Although patients were referred by
their primary providers to the sessions, 13% indicated that
they had never heard of HCV. Among those who had heard
of HCV, 64% learned about HCV from their primary care
providers and the rest of the subjects had most commonly
heard of HCV from friends/family members, magazines/
books/newspapers, and media. The majority of subjects
were interested in receiving HCV therapy (97%).
At baseline, the overall mean percent knowledge score
was 61. The percent baseline HCV knowledge scores were
signiﬁcantly higher in individuals with age less than
45 years (68 vs. 58, p = 0.01), White race (70 vs. 53,
p = 0.007), high school and above education (66 vs. 56,
p = 0.006), income less than $15,000 per year (65 vs. 51,
Table 1 Summary of
components of HCV knowledge
questionnaire
Multiple-choice questions Correct at
baseline (%)
Hepatitis C is caused by? 83
What is hepatitis C? 51
How does a person know that he/she has hepatitis C? 65
What is the treatment for hepatitis C? 65
What are the side-effects of treatment for hepatitis C? 51
True or false questions
Hepatitis C is a common chronic disease 51
Hepatitis C has different genotypes 44
Genotype 1 is the most common in the United States 27
Hepatitis C usually has no symptoms 37
Hepatitis means inﬂammation of the liver 89
Alcohol makes hepatitis C disease worse 95
Most people with hepatitis C develop liver cancer 54
Most people with hepatitis C do not develop cirrhosis 29
Most people with hepatitis C eventually need a liver transplant 69
People with HIV can also receive hepatitis C treatment 79
Liver biopsy is helpful in assessing damage to the liver from hepatitis C 78
There are vaccines available for
Hepatitis A 74
Hepatitis B 76
Hepatitis C 38
How does a person get or spread hepatitis C?
Sharing needles 88
Blood transfusion 83
Through childbirth 35
Hugging 58
Toilet 61
Sexual intercourse 63
Tattoos/piercings 78
Sharing food/utensils 57
Sharing razor 74
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123p = 0.0001), exposure to hepatitis B (72 vs. 60, p =
0.003), and current or prior history of IDU (65 vs. 53,
p = 0.001). On multivariate analysis, education of high
school and above was independently associated with higher
baseline knowledge scores and African American (com-
pared to White) race and older age were associated with
lower baseline knowledge scores (Table 3).
Following HCV education, the mean percent knowledge
score improved by 14 points (61–75, p\0.0001). Patients
speciﬁcally gained the most knowledge in three categories
(Table 4): HCV transmission (mean change in percent
score = 10, p = 0.0003), HCV general knowledge (mean
change in percent score = 16, p = 0.02), and health care
maintenance (mean change in percent score = 17, p =
0.004). Although there was an improvement in knowledge
in the categories of HCV diagnosis, HCV natural history,
and HCV therapy, these changes did not reach statistical
signiﬁcance.
There was a greater increase in HCV knowledge in those
who were employed (mean change in percent score 19 vs.
13, p = 0.01). Other potential predictors such as gender,
age, racial background, US birth, education level, marital
status, mode of acquisition of HCV, alcohol use or IDU
use, methadone maintenance therapy, and presence of HIV
coinfection were not different. On multivariate analysis,
the only independent predictor of change in HCV knowl-
edge after education was interest in obtaining medical care
for medical conditions. Patients who were interested in
obtaining medical care had a 6.7% (95% CI -11.3 to -2.1,
p = 0.005) lower change in knowledge scores after edu-
cation compared to those who were not interested in
obtaining medical care.
Interest in HCV Treatment and Specialty Referral After
Education
After education, once again the majority of subjects (94%)
indicated that they were interested in HCV treatment and
referral to a liver specialist. Since 2005, interested HCV
patients have been scheduled in the liver specialty clinics
within the San Francisco safety net system following
approval by a hepatologist who reviews the electronic
referral submitted by the primary provider and who
Table 2 Patient characteristics (n = 201)
Age mean ± SD (years) 49 ± 10
Males (%) 136 (69)
Race/ethnicity (%)
Caucasian 96 (49)
African American 51 (26)
Latino 20 (10)
Asian/Paciﬁc Islander 13 (7.0)
Other 15 (8)
Born in United States (%) 161 (83)
Married/living together (%) 29 (15)
Temporary housing or homeless (%) 36 (18)
Employed (%) 48 (25)
Income: $15,000 or less (%) 135 (74)
High school and above education (%) 159 (83)
HIV co-infection (%) 14 (7)
Methadone maintenance/drug
rehabilitation program (%)
31 (16)
Current alcohol use (%) 21 (13)
History of heavy alcohol use[50 g/day (%) 100 (59)
HCV risk factors (%)
IDU 125 (64)
Blood transfusion 49 (26)
Sexual 17 (9)
Other 10 (5)
Never heard of hepatitis C (%) 25 (13)
Prior treatment of hepatitis C (%) 23 (12)
Table 3 Multivariate analysis of predictors of knowledge scores
prior to HCV education
Variable Coefﬁcient 95% CI* p value**
Age -0.7 -1.3 to -0.8 0.03**
Female gender -1.8 -10 to 6.5 0.7
Race (compared to White)
African American -12.3 -20.8 to -3.9 0.004**
Latino -10.0 -23.9 to 3.83 0.2
Asian 1.8 -23.2 to 26.8 0.9
Other -5.0 -19.9 to 9.9 0.51
Education: high school
and above
7.1 0.2 to 14.0 0.045**
IDU -5.1 -13.3 to 3.2 0.2
Methadone maintenance 6.2 -3.6 to 15.9 0.2
Current alcohol use -0.06 -0.6 to 0.5 0.8
High interest in obtaining
medical care
7.2 -0.4 to 14.8 0.06
* 95% conﬁdence intervals; ** p\0.05 is considered signiﬁcant
Table 4 Change in knowledge score after HCV education
Knowledge categories Mean change in %
knowledge score
95% CI* p value**
HCV transmission 10 6 to 14 0.0003**
HCV diagnosis 9 -56 to 74 0.3
HCV knowledge 16 3 to 29 0.02**
Natural history of HCV 13 -4 to 30 0.1
HCV treatment 10 -7 to 29 0.2
Health care maintenance 17 12 to 22 0.004**
* 95% conﬁdence intervals; ** p\0.05 is considered signiﬁcant
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123determines potential candidacy of the patient for HCV
treatment work-up. Before initiation of the HCV education
class (historical control) and during the same length of time
as the study period (19 months), 322 patients were referred
to the liver specialty clinics and 180 (56%) were scheduled
in the liver specialty clinics. A similar number of patients
were referred (n = 358) and scheduled (n = 206, 58%) in
the liver specialty clinics during the study period (p = 0.4).
However, there were signiﬁcantly higher show rates in the
liver specialty clinics among those who were scheduled
after initiation of mandatory education class than the his-
torical controls who did not receive disease-speciﬁc formal
education (64 vs. 39%, p\0.0001). The characteristics of
patients who were scheduled in the liver clinic and attended
their visit during the study period was similar to the his-
torical control with respect to mean age (52 ± 11 vs.
53 ± 10 years, p = 0.4), gender (proportion male 59 vs.
65%, p = 0.4), and race (White 38 vs. 35%, African
American 22 vs. 34%, Latino 17 vs. 10%, p = 0.3).
Long-Term Retention of HCV Knowledge
After Education
Nineteen study subjects who attended the liver specialty
clinic after HCV education agreed to complete the same
post-education questionnaire at the time of their clinic visit
to evaluate retention of HCV knowledge. The primary
reason for low response rates was related to the time
constraints on patients (and providers) to complete the
questionnaire during the busy clinic setting. In these
patients, their HCV knowledge immediately after educa-
tion had substantially improved compared to before edu-
cation (mean percent score 45–64, p = 0.005). The median
time elapsed between attending the HCV education class
and liver clinic visit was 4 months (range 1–13 months).
The mean percent knowledge scores at the time of liver
clinic attendance were similar to that immediately fol-
lowing education session (61 vs. 65, p = 0.7) suggesting
that HCV knowledge following education can be retained
long-term.
Discussion
In this study, we have shown that HCV education sub-
stantially improves patient knowledge of HCV disease in
the vulnerable, ethnically diverse, safety net population.
Although we identiﬁed gaps in almost all areas of HCV
knowledge, patients gained the most knowledge in the
categories of general HCV disease knowledge, HCV
transmission, and health care maintenance. We also
showed that HCV knowledge may possibly be retained
long-term. Moreover, there were substantially higher liver
clinic show rates compared to those who were not offered
disease-speciﬁc education.
Our education session was specially designed to
encompass all aspects of HCV disease management from
diagnosis, transmission, natural history, candidacy for
treatment, and beneﬁts and adverse effects of therapy, to
resources for access to specialty care and general health
care maintenance. In a study of 115 patients with newly
diagnosed HCV, the most common volunteered patient
concerns included disease progression, premature death,
infecting family members and side-effects of treatment [3].
This highlights the necessity for a comprehensive HCV
educational program such as that implemented in our study
in order to adequately address patient’s concerns.
We have shown that African American race, older age,
and lower level of education are independently associated
with lower HCV knowledge. This is consistent with dis-
parities of access to care that have been previously
described in the vulnerable populations [7, 12]. Similarly,
in a cohort of 110 patients attending a methadone detoxi-
ﬁcation and methadone maintenance program in San
Francisco, Walley et al. [7] showed that White race and
Latinos had signiﬁcantly higher knowledge of HCV treat-
ment than African Americans. However, we have also
shown that the gain in knowledge after education was
similar across all ages, genders, and racial background,
suggesting that HCV education can play an important role
in reducing health care disparity in this population. The
fact that patients who were interested in obtaining medical
care had a lesser change in knowledge scores after edu-
cation was likely because these patients were well
informed about HCV disease at baseline with higher
knowledge scores compared to those who were not inter-
ested in obtaining medical care (66 vs. 58%, p = 0.05).
Prior studies have shown a large gap in HCV knowledge
about HCV therapy in IDUs [7, 13]. We found that IDUs
had 12% higher baseline knowledge scores compared to
other HCV-infected individuals. This may reﬂect height-
ened awareness of HCV in this population due to the high
prevalence of HCV among peers, exposure to substance
abuse counselors and mental health professionals, and
potentially integrated substance abuse and HCV manage-
ment in this population [14]. This result also suggests that
there is likely a great need in educating individuals with
modes of acquisition of HCV other than IDU.
Despite being engaged with the health care system and
being referred by their primary providers, 13% of our study
subjects had never heard of HCV prior to the session and
36% had become aware of HCV from sources other than
primary providers. A survey of 388 family physicians in
New Jersey showed that family physicians had insufﬁcient
knowledge about screening and counseling for chronic
hepatitis and 83% of respondents were interested in
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123receiving education about chronic hepatitis [15]. In addi-
tion, a survey of 629 chronically infected veterans showed
that only 60% of patients who attended liver specialty care
underwent formal HCV education [11]. While our study
was not designed to address health system or institutional
barriers to access to HCV care, the initiation of an edu-
cational session provided by liver specialists along with
a patient-centered approach to HCV management has
substantially improved access to HCV care in our popu-
lation. A signiﬁcantly higher proportion of patients atten-
ded their liver specialty clinic visit after initiation of the
educational sessions, and about 30% had received HCV
therapy during the study period. In addition, the wait times
for liver specialty clinic appointments have been reduced
from 6 to 2 months in our safety net system.
Since the HCV education class was instituted as a
mandatory component of referral of patients with HCV to
the liver specialty clinics in this safety net system, the
study was limited by a lack of randomization of patients to
education versus no education class in determining the
rates of liver specialty clinic attendance. However, we were
able to utilize a historical control of HCV patients prior to
initiation of education class to compare liver specialty
clinic show rates in those with scheduled appointments.
Both the study patient cohort and the historical controls
likely represent individuals who are motivated to receive
HCV therapy and management. Therefore, selection bias is
unlikely to play a role in our ﬁnding that HCV education
signiﬁcantly improves liver specialty clinic attendance
rates when these cohorts are compared. The low response
rate to the questionnaire in the busy clinic setting was
primarily related to the time constraints on patients and
selection and/or reporting biases are less likely to have
played a signiﬁcant role in the reported retention of HCV
knowledge long-term in nearly one-quarter of patients.
Nevertheless, this result requires conﬁrmation with a larger
number of patients.
In summary, education plays an important role in
improvement of HCV knowledge in HCV-infected sub-
jects. Although African Americans and older individuals
had lower baseline HCV knowledge, the improvement of
HCV knowledge was observed across all ages, racial
backgrounds, IDUs, education levels, and socioeconomic
status. As vulnerable populations are disproportionally
affected by HCV and adverse disease outcomes, this sug-
gests that promoting effective HCV educational programs
among vulnerable populations may be an important factor
in reducing the disparities in HCV disease. Prior studies
have shown that HCV patients consider HCV education as
an important HCV health care need that results in a marked
increase in willingness to accept HCV treatment [16, 17].
A patient-centered approach to health care in HCV-infec-
ted vulnerable population is likely to result in higher
compliance with pursuing HCV health care and potentially
create efﬁciencies in the health system to better access
specialty care for these individuals.
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